Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
To access this article, please choose from the options below
PII: S0959-8049(09)00730-8
doi:10.1016/j.ejca.2009.10.005
© 2009 Elsevier Ltd. All rights reserved.
